Reference
Xia H, et al. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clinical Lung Cancer 21: 247-254, No. 3, May 2020. Available from: URL: http://doi.org/10.1016/j.cllc.2019.09.004
Rights and permissions
About this article
Cite this article
Afatinib/gefitinib/osimertinib. Reactions Weekly 1806, 21 (2020). https://doi.org/10.1007/s40278-020-79039-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-79039-8